Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Interest & Investment Income: 2022-2025

Historic Interest & Investment Income for Roivant Sciences (ROIV) over the last 4 years, with Mar 2025 value amounting to $258.4 million.

  • Roivant Sciences' Interest & Investment Income fell 35.02% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.3 million, marking a year-over-year increase of 19.74%. This contributed to the annual value of $258.4 million for FY2025, which is 76.46% up from last year.
  • Latest data reveals that Roivant Sciences reported Interest & Investment Income of $258.4 million as of FY2025, which was up 76.46% from $146.4 million recorded in FY2024.
  • In the past 5 years, Roivant Sciences' Interest & Investment Income registered a high of $258.4 million during FY2025, and its lowest value of $369,000 during FY2022.
  • Its 3-year average for Interest & Investment Income is $145.7 million, with a median of $146.4 million in 2024.
  • Data for Roivant Sciences' Interest & Investment Income shows a peak YoY surged of 8,621.95% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Roivant Sciences' Interest & Investment Income stood at $369,000 in 2022, then skyrocketed by 8,621.95% to $32.2 million in 2023, then soared by 354.96% to $146.4 million in 2024, then soared by 76.46% to $258.4 million in 2025.